Falcon Pharmaceuticals, Ltd. company specializes in making generic equivalents of ophthalmic drugs that treat a range of eye conditions, as well as otic (ear) and nasal ailments. Its lead product, Timolol GFS, is a generic equivalent of Merck's glaucoma treatment Timoptic-XE gel. Falcon Pharmaceuticals company also offers anti-infective, steroid, anti-viral, anti-allergy, and anesthetic pharmaceutical products without the markup typically associated with brand names. Falcon Pharmaceuticals is a subsidiary of eye care products company Alcon.

Palatin Technologies, Inc. company was founded in 1986 and is based in Cranbury, New Jersey. Palatin Technologies, Inc., a biopharmaceutical company, engages in the discovery and development of peptide, peptide mimetic, and small molecule agonist compounds with a focus on melanocortin (MC) and natriuretic peptide receptor systems in the United States. The company's products under development include PL-3994, a peptide mimetic natriuretic peptide receptor A agonist for the treatment of heart failure; Bremelanotide, a peptide melanocortin receptor agonist for the treatment of sexual dysfunction, targeting female sexual dysfunction and erectile dysfunction in patients non-responsive to current therapies; and PL-6983, a peptide melanocortin receptor agonist for the treatment of female sexual dysfunction. Its products in development also comprise melanocortin receptor-based compounds for treatment of obesity, diabetes, and related metabolic syndrome; and NeutroSpec, a radiolabeled monoclonal antibody product for imaging and diagnosing infection. Palatin Technologies, Inc. has a licensing and research collaboration agreement with AstraZeneca AB to discover, develop, and commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes, and related metabolic syndrome.

Myriad Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel small molecule drugs for the treatment of diseases with high unmet need, including cancer and HIV infection. Its pipeline includes clinical and pre-clinical product candidates with mechanisms of action and novel chemical structures. The company's product candidates in clinical development include Azixa (MPC-6827), which is under Phase II clinical trial for the treatment of glioblastoma multiforme and metastatic melanoma; MPC-4326 for HIV-1 infection under Phase IIb clinical trial; and MPC-3100, a Phase I clinical trial product candidate for cancer treatment. Its products in preclinical programs comprise MPI-443803, an orally available, brain penetrant, microtubule destabilizing agent for the treatment of cancer; and MPI-461359, an orally available maturation inhibitor for the treatment of HIV-1 infection, as well as MPI-479605 for the treatment of cancer. The company also offers ProNet, a proprietary database of protein-protein interactions, which encompasses interactions between approximately 10 million protein fragments constructed from various organ tissues, including heart, brain, kidney, liver, breast, and prostate. Myriad Pharmaceuticals, Inc. is based in Salt Lake City, Utah.

BioSante Pharmaceuticals, Inc. company was founded in 1996 and is based in Lincolnshire, Illinois. BioSante Pharmaceuticals, Inc., a biopharmaceutical company, develops products for female sexual health, menopause, contraception, and male hypogonadism. It develops calcium phosphate nanotechnology for aesthetic medicine, novel vaccines, and drug delivery. The company's products include LibiGel, a transdermal testosterone gel in Phase III development for the treatment of female sexual dysfunction; Elestrin, a transdermal estradiol (estrogen) gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause; Bio-T-Gel, a transdermal testosterone gel in development for the treatment of hypogonadism, or testosterone deficiency in men; and the Pill-Plus for the treatment of female sexual dysfunction in women using oral or transdermal contraceptives. The company's CaP products in development comprise BioLook, which is facial line filler in development using proprietary CaP technology in the area of aesthetic medicine; BioVant for the treatment of viral and bacterial infections and autoimmune diseases; BioOral, a delivery system using CaP technology for oral/buccal/intranasal administration of proteins and other therapies; and BioAir, a delivery system using CaP technology for inhalable versions of proteins and other therapies.

Helicon Therapeutics is a development-stage biotechnology firm working on new therapies for memory loss and other cognition disorders. The company's research and development efforts focus on a protein that controls the signal pathway key to forming long-term memories. Scientists working for Helicon Therapeutics discovered the protein while studying the fruit fly genome. The company is working on drugs to not only maintain memory but also possibly to prevent memories from forming in the first place. Lead drug candidate HT-0712 has shown the ability to improve long-term memory in rats. Other candidates are in early stages of development.

Insys Therapeutics, Inc. company focuses on developing drugs for treating side effects of chemotherapy (such as nausea), as well as therapies for pain management and other central-nervous-system conditions. Its Dronabinol HG candidate, a generic capsule form of Marinol awaiting FDA approval, may treat chemotherapy-induced nausea and vomiting. The firm is also developing inhalation and room-temperature capsule and syrup forms of Dronabinol. In addition, its Fentanyl SL spray, delivered under the tongue for quick absorption, treats pain in cancer patients. All of the company's drug candidates are unique formulations of already-approved therapeutic ingredients.

Ash Stevens, Inc. was founded in 1962 to provide chemical research for the government and later branched out into the private sector. Ash Stevens, Inc. company, a contract pharmaceutical manufacturer develops and manufactures active pharmaceutical ingredients (APIs) for other pharmaceutical companies. It also supports clinical drug trials and helps others navigate the FDA's regulatory maze. Its customers include the federal government and commercial pharmaceutical firms. The company's portfolio includes about a dozen FDA-approved drug components.

Founded in 1929, the not-for-profit organization is a leading researcher of human diseases, their causes, and their potential cures. Much of its research into mammalian genetics is focused on mice, which share a similar genetic makeup to humans. In addition to its own research in areas such as cancer, immunology, and metabolic disease, the organization maintains colonies of mice and supplies them under the brand name JAX to other laboratories around the globe. Additionally, The Jackson Laboratory offers educational programs -- including internships, workshops, and predoctoral programs -- for both current and future scientists.

NovaDel Pharma is developing new ways to deliver popular over-the-counter and prescription drugs...just make sure you don't grab your cologne by mistake. NovaDel company's proprietary oral spray delivery system allows for faster absorption into the bloodstream, in turn producing therapeutic benefits more quickly. NovaDel won FDA approval of its first product, NitroMist (an oral spray formulation of a common angina treatment), in 2006; the company is looking for a partner to market the drug. The company received FDA approval of its ZolpiMist, a spray version of Sanofi-Aventis' insomnia drug Ambien, in 2008. It is also developing spray versions of treatments for nausea, migraine, and central nervous system disorders.

SkinMedica, Inc. was founded in 1999 and is headquartered in Carlsbad, California. SkinMedica, Inc. operates as a specialty pharmaceutical company that focuses on developing, acquiring, and commercializing products that treat dermatologic conditions and diseases and enhances the appearance of skin. It offers gels for the treatment of mild to moderate atopic dermatitis; creams for the reduction in growth of unwanted facial hair in women; franchises for the treatment of acne; and products for the treatment of hyperpigmentation. The company also provides anti aging products, aesthetic skin care, moisturizers, and sun protection, eye products, as well as facial and sensitive skin cleansers, rejuvenative and acne treatment toners, and skin polishers. It markets and sells prescription pharmaceutical products, and physician-dispensed and non-prescription skin care products primarily to dermatologists and pediatricians.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.